Issue 46 - The Cancer Letter

<img class="lazy" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://cdn.cancerletter.com/media/2021/03/17053004/TCL-logo-horizontal-white.png" alt="" >

Vol.

9

No.

46

December 02, 1983Dec 02, 1983

Free

DOWNLOAD THE PDF

Full Funding Of Indirect Costs, Other Mandates By Congress Chew Up Most Of NCI’s Extra Money

In Brief: VP-16 NDA Approved By FDA Only For Refractory Testicular Cancer; Removed From Group C List

Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now

Cooperative Group Chairman Unhappy Over Exclusion From Funding at Recommended Levels

Workshop Calls For Improved Surgical Oncology Training Programs

Recent Issues

Volume 51 | Issue 32 - September 05, 2025

Volume 51 | Issue 31 - August 08, 2025

Volume 51 | Issue 30 - August 01, 2025

Volume 51 | Issue 29 - July 25, 2025

Volume 51 | Issue 28 - July 18, 2025

Volume 51 | Issue 27 - July 11, 2025